1. Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)
   Svetlana Spremović Rađenović et al, 2022, Biomedicines CrossRef
2. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma
   Elizabeth R. M. Zunica et al, 2022, Cancers CrossRef
3. Efficacy of orlistat in obese patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
   Abdelrahman Mahmoud et al, 2024, Baylor University Medical Center Proceedings CrossRef
4. Management of metabolic-associated fatty liver disease: The diabetology perspective
   Mohammad Sadiq Jeeyavudeen et al, 2023, World Journal of Gastroenterology CrossRef
5. Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice
   Chongming Wu et al, 2019, Marine Drugs CrossRef
6. Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective
   Moein Ala et al, 2023, Obesity Reviews CrossRef
7. Resistant Maltodextrin Ameliorates Altered Hepatic Lipid Homeostasis via Activation of AMP-Activated Protein Kinase in a High-Fat Diet-Fed Rat Model
   Shing-Hwa Liu et al, 2019, Nutrients CrossRef
8. Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling
   Bo-Ram Jin et al, 2021, Cells CrossRef
9. Nutraceuticals for Non-alcoholic Fatty Liver Disease
   Alper Sonmez et al, 2021, Nutraceuticals and Cardiovascular Disease CrossRef
10. Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
    Yuping Ding et al, 2023, Diabetes, Metabolic Syndrome and Obesity CrossRef
11. Sweet potato extract alleviates high-fat-diet-induced obesity in C57BL/6J mice, but not by inhibiting pancreatic lipases
    Tiange Liu et al, 2022, Frontiers in Nutrition CrossRef
12. The Effect of Orlistat on Sterol Metabolism in Obese Patients
    Yu-Jin Kwon et al, 2022, Frontiers in Endocrinology CrossRef
13. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
    Stergios A. Polyzos et al, 2022, Current Obesity Reports CrossRef
14. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
    Michele Finotti et al, 2021, Journal of Personalized Medicine CrossRef